Introduction
============

Diacetyl is a flavoring commonly used in foodstuffs, as it lends a buttery flavor to products such as popcorn, coffee blends, cakes, cookies, wines and other goods ([@ref-20]; [@ref-33]; [@ref-30]; [@ref-27]; [@ref-28]; [@ref-25]). It is a volatile α-dicarbonyl and a highly electrophilic compound ([@ref-30]) approved worldwide for use by food industries, despite ongoing health concerns dating back to 1986 ([@ref-26]), when the first cases of bronquiolitis obliterans involving diacetyl emerged ([@ref-28]; [@ref-15]; [@ref-13]).

Recently, we reported that the reaction of peroxynitrite with α-dicarbonyls, namely diacetyl and methylglyoxal, in aerated phosphate buffer pH 7.4 results in the acetylation of free amino acids, peptides and proteins added to the reaction mixture ([@ref-1]; [@ref-18]; [@ref-17]; [@ref-37]). This reaction is initiated by nucleophilic addition of peroxynitrite to the carbonyl group of the α-dicarbonyl compound yielding a peroxynitroso adduct, whose homolysis yields acetyl radicals. Dissolved molecular oxygen adds to the radical to ultimately produce acetate from diacetyl or acetate and formate from methylglyoxal ([@ref-18]; [@ref-17]). Formyl radical intermediate generated by methylglyoxal/peroxynitrite was shown to add to the α-amino group of L-lysine-containing synthesized tetrapeptides ([@ref-37]). On the other hand, diacetyl/peroxynitrite-generated acetyl radicals have proven been proven to attack both the α- and ε-amino groups of free and blocked L-Lys, L-Lys-containing peptides and serum albumin ([@ref-1]). These findings have raised the hypothesis that radical acetylation of proteins contributes to transacetylase--promoted, post-translational protein modifications at sites where both methylglyoxal or diacetyl and peroxynitrite are present ([@ref-1]; [@ref-18]; [@ref-17]; [@ref-37]). From these facts, the competition of chemical (induced by diacetyl) and enzymatic (occurring naturally in organisms) acetylation can be inferred, with the former process contributing to the increase of total protein acetylation.

Another source of acetylation *in vivo* is found through the action of acetyltransferases. These enzymes reversibly catalyze the transfer of the acetyl group from acetyl-CoA to the ε-amino group of protein lysine residues ([@ref-8]), a process promoted by lysine acetyltransferase and lysine deacetylase ([@ref-22]; [@ref-2]; [@ref-12]) at the N-terminus during the synthesis of proteins. Protein acetylation is highly conserved in eukaryotes and prokaryotes than phosphorylation, but it is less common than phosphorylation and ubiquitination ([@ref-21]). Acetylation can reportedly alter the protein function, size, enzymatic activity, stability, protein-protein interactions and other protein properties. When acetyltransferase is deregulated, and lysine acetylation is increased, modifications may occur in genes and in the regulatory machinery, resulting in the manifestation of tumours in cells ([@ref-8]). On the other hand, ATP-dependent acetylation has recently been reported to play a role in many cellular processes such as catalytic activity, immune responses and metabolic processes, including the generation of precursors of "energy-rich" metabolites such as acetylphosphate (acP). AcP-dependent acetylation tends to govern the translation of nucleotides, purine and pyrimidine metabolism and degradation of RNA ([@ref-16]).

In this work, we use proteomic and western blotting techniques to investigate if diacetyl is also capable of leading to increases *in vivo* protein acetylation. Based on our findings, we support the hypothesis that diacetyl exposure in animals may lead to increases in protein acetylation, which may affect protein functions and trigger adverse health problems.

Methods
=======

Animal treatment
----------------

All animals were fed *ad libitum* and kept in a cabinet at 50--70% humidity, at a temperature of 19--26 °C in a cycle of 12 h light/12 h dark. This study adheres to the guidelines established by the Brazilian College of Animal Experimentation (COBEA) and was approved by the Ethical Committee of the School Medicine of the Federal University of São Paulo (UNIFESP, protocol no. 1949-11).

Eight-to-twelve-week-old male Wistar rats (250--300 g) were divided into two groups (6 animals each). The control group received phosphate-buffered saline (PBS), while the treated group received 540 mg/kg/day of diacetyl (Cat B8530-7; Sigma Aldrich, St. Louis, MO, USA) dissolved in PBS Both groups were dosed using gavage. The concentration of 540 mg/Kg/day of 2,3-butanedione and the treatment period of four weeks was based on the experiment conducted by Colley and Cols ([@ref-6]).

After four weeks of treatment, the animals were anesthetized with ketamine and xylazine (Sigma Aldrich, St. Louis, MO, USA) and sacrificed. The lung tissue was collected and immediately frozen in liquid nitrogen and stored at --80 °C.

Preparation of lung extracts
----------------------------

### Tissue preparation

Frozen lungs were ground into a fine powder in liquid nitrogen using a mortar and pestle. The homogenization process was used to avoid the activation of proteases and prevents protein degradation. The sample was lyophilized prior to analysis in order to remove residual water and stabilize the sample for handling at room temperature, thereby facilitating the weighing process and preparation of the sample.

### Protein extraction optimization

Due to the wide range of proteins and interfering substances in the final extracts, the samples were obtained in the following three steps prior to proteomics analysis: tissue disaggregation and cell homogenization; protein extraction from the biological matrix; and protein precipitation and solubilisation in a urea buffer.

Three methods of protein extraction were tested to quantify the amount of protein in the lysates before and after precipitation ([Table 1](#table-1){ref-type="table"}). Thirteen milligrams of lyophilized lung suspended in one mL of extraction buffer were used.
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###### Composition of the tested buffers.
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  Composition           Buffer 1[^a^](#table-1fn1){ref-type="fn"}                  Buffer 2[^b^](#table-1fn2){ref-type="fn"}                  Buffer 3[^c^](#table-1fn3){ref-type="fn"}
  --------------------- ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Buffering agent       Tris 25 mM                                                 Tris 25 mM                                                 Tris 25 mM
  Surfactant            CHAPS 2%                                                   CHAPS4% TRITON 1%                                          CHAPS 4%
  Protease inhibitors   Aprotinine, leupeptine, pepstatine, benzamidine and PMSF   Aprotinine, leupeptine, pepstatine, benzamidine and PMSF   Aprotinine, leupeptine, pepstatine, benzamidine and PMSF
  Chaotropes                                                                                                                                  7 M Urea
                                                                                                                                              2 M Thiourea
  Reducer                                                                                                                                     65 mM DTT

**Notes.**

Buffer 1 with power low solubility (few surfactants without chaotropes).

Buffer 2 with median solubilizing power (more surfactants).

Buffer 3 with maximum solubilization power (presence of chaotropes, surfactants and reducers).

The lung powder was suspended and shaken for 1 h at 4 °C. After centrifugation (10 min, 5,000 × RPM, 4 °C), 200 µL of the supernatant was mixed with 800 µL of DTT solution in cold acetone (2 mg/mL) and incubated overnight at −20 °C. Afterwards, the samples were centrifuged (10 min, 16,000 × RPM, 4 °C), and the sediments were washed four times with the DTT solution, dried in vacuum and solubilized in urea buffer (7 mol L^−1^ urea, 2 mol L^−1^ thiourea, 4% CHAPS). The total protein concentration was determined by the Bradford method ([@ref-3]).

Tryptic digestion
-----------------

Prior to tryptic digestion, polypropylene microtubes were individually filled with an extract aliquot containing 250 µg of the lung protein. The samples were reduced with Dithiothreitol (DTT) solution until achieving a final concentration of 5 mmol L^−1^, and they were then incubated for 25 min at 56 °C. To achieve alkylation in the samples, iodoacetoamide (IAA) was added until reaching a final concentration of 14 mmol L^−1^. The samples were then incubated for 30 min at room temperature and protected from light. Afterward, they were diluted until the concentration of urea was reduced to 1,600 mmol L^−1^, and a CaCl~2~ solution was added until reaching a final concentration of 1 mmol L^−1^ of CaCl~2~.

The enzymes trypsin and LysC endoproinase were added in the ratio of 1:50 of (enzyme: substrate). The samples were incubated for 18 h at 37 °C. The enzyme reaction was stopped by adding TFA (trifluoroacetic acid) at the final concentration of 0.4%. The samples were centrifuged at 2,500 rpm for 10 min at room temperature, and the pellet was discarded. The sample was evaporated until the volume was reduced to approximately 50 µl using a vacuum concentrator (Speed Vacuum; Thermo Fisher Scientific, Waltham, MA, USA). Finally, 50 µl of 0.5% trifluoroacetic acid (TFA) were added thereto. Detergents were removed from the sample using a Pierce detergent removal spin column (\# 87776; Pierce Biotechnology/Thermo Fisher Scientific, Waltham, MA, USA), which was used according to the manufacturer's specifications; the samples were filtered through a 22 µm PVDF syringe filter stocked at 4 °C for mass spectrometry analysis.

NanoLC--ESI/MS/MS analyses
--------------------------

In this study, on average six biological replicates and two replicate techniques were used. However, due to technical problems, we used 11 replicates of the control group and 10 replicates of the group treated with 540 mg/kg/day of diacetyl. Each trypsinized sample was dissolved with 100 µL of a mixture of water/acetonitrile/TFA (949:50:1 v/v). All analyses were performed using a Nano-UHPLC Advance (Bruker Daltonics, Bremen, Germany) equipped with a pump, an auto sampler, and a thermostatically controlled column compartment. A C18 reversed-phase column (Magic C18 AQ, P/N: CP3/61271/00; Michrom, Boise, ID, USA), particle size 3 µm, internal diameter 0.1 mm, length 100 mm was used. The column temperature was kept at 40 °C. Samples were separated using a gradient mobile phase consisting of (A) formic acid/ACN/H~2~O (1:20:979) and (B) formic acid/ACN/H~2~O (1:950:50) in a gradient elution from 2 to 50 % over 150 min, as a graph in SM1. The flow rate was set at 0.500 µL/min, and the injection volume was 5 µL. Detections were performed using a micrOTOF-Q II (Bruker Daltonics, Billerica, MA, USA), an accurate mass instrument equipped with captive source (Bruker Daltonics, Billerica, MA, USA) and an electrospray-ionization source (ESI). The mass spectrometer was running in positive mode, with the desolvation temperature at 180 °C and the nebulizer set at 500 V and 0.4 bars. All the operations, acquisition, and analysis of data were controlled by Hystar software version 1.7 (Bruker Daltonics, Billerica, MA, USA). For MS/MS analyses, five precursor ions were automatically selected to undergo collision and fragmentation with argon gas (≥ 2 L/min). Mass spectra were collected between 50 to 3,000 *m/z,* and calibration was performed at the beginning of every day using the Tune-Mix ESI-G (Agilent Technologies, Santa Clara, CA, USA). The collision energy was 12 eV, collision RF 600 Vpp, transfer time 140 µs, and pre-pulse storage 14 µs. MS/MS parameters were three precursor ions, absolute threshold 2,000 cts, smart exclusion 5 ×, excluded after three spectra, and released after 1 min. The tune parameters were Funnel 1RF 300 Vpp, Funnel 2 RF 400 Vpp, hexapole RF 400 Vpp, quadrupole ion energy 6.0 eV, and low mass 300 m/z. The TOF (time of flight) conditions included the following: repetition rate 5 kHz, sample rate 2 Ghz, flight tube 8,600 V, reflector 1,700 V, detector source 1,700 V, and detector TOF 2140 V. Argon was used as a collision gas at a pressure of 2 ×10^−6^ mbar, and the collision energy values were 10--200 eV.

Bioinformatic analysis
----------------------

### Data deconvolution and database search

Data from mass spectrometry were processed using a Compass 1.7 for OTOF (Bruker Daltonics, Billerica, MA, USA) and deconvoluted to generate a file compatible with Mascot. This file was analyzed using Protein Scape (Bruker Daltonics, Billerica, MA, USA), a program that uses Mascot algorithms to perform the search. The database used was Swissprot, an annotated protein sequence database. The taxonomy was *rattus*, and the enzyme was trypsin with two missed cleavages. The fixed modification was carbamidomethylation, and the variable modifications were oxidation of methionine and acetylation of lysine and arginine. Mass tolerance modification was 150 ppm to 1 Da. Mascot analysis of all proteins (*p* \< 0.05) used a minimum score of 35.

### Protein network analysis

The protein-protein interaction analysis was performed using Cytoscape 3.3.0 software (<http://www.cytoscape.org/>) ([@ref-32]), and the protein interaction network was obtained from the STRING 8.2 database (<http://string-db.org/>) ([@ref-36]). STRING 8.2 uses the metric of "confidence score" to define the confidence of the interactions. We selected only the interactions with proteins identified in our analyses.

### Orthologs analysis

Orthologs were subjected to Gene Ontology (GO) term analysis based on PANTHER classification online tools (<http://pantherdb.org/>). To determine the biochemical functions of acetylated proteins detected in the lungs of the group treated with diacetyl, GO was performed using IDs with the *Rattus norvegicus* genome found in the Uniprot database. This particular database was chosen as the reference database for the output report of biologicals process, proteins class, cellular components, pathways and molecular functions ([@ref-23]). These analyses were performed to acquire insights of the acetylation involved in the functions and pathways of proteins.

### Analysis of sequence model around acetylated lysine

The software motif-x was employed to determine specific sequences of amino acid (15 amino acids upstream and downstream of the acetylation site) in all protein sequences acquired from NanoLC-MS/MS analysis. The entire database (IPI Rat Proteome) was used as a background database parameter, and the significance was 0.000001 ([@ref-5]; [@ref-31]).

### Western blotting

Samples containing 25 µg of proteins from lung homogenate were subjected to 12% SDS--PAGE electrophoresis and electroblotted onto a nitrocellulose membrane (Millipore, USA). Following the blocking and washing steps, the membranes were incubated with the primary Acetylated-Lysine antibody (Cell Signalling, Danvers, MA, USA) and anti-rabbit IgG HRP-linked (Cell Signalling, Danvers, MA, USA) as a secondary antibody. The membranes were then detected using a chemiluminescence kit "Pierce ECL Plus Western Blotting Substrate" (Thermo Scientific, Waltham, MA, USA) and chemiluminescence software (GeneGnome System/Gene Tools Software; Syngene, Cambridge, UK).

Results
=======

Protein extraction optimization
-------------------------------

We performed three different protein extraction methods to determine which one yielded the most consistent results when reproduced. That method was then adopted, allowing for increased accuracy in the estimation of protein amounts from the lysate extracts. [Figure 1](#fig-1){ref-type="fig"} shows a comparison of the amount of proteins between lung lysate and the solution of precipitate lung proteins resuspended.

![Comparison of the amount of total protein present in the lysate and the resolubilizated proteins (precipitate proteins resuspended) using lung tissue.](peerj-06-4688-g001){#fig-1}

MS/MS analyses of rat lung proteins
-----------------------------------

In this work, qualitative proteomic analysis was used, specifically the *bottom up* technique. The lung extracts were analyzed by NanoLC-MS/MS, and significant differences were shown among the protein profiles in the control and diacetyl-treated groups. Acetylation was set in the search engine as a variable modification, and overall, the analyses showed 10,302 peptides identified as belonging to 603 proteins in lung tissue. A set of 327 acetylated proteins in the control group and 351 proteins in the group treated with 540 mg/kg/day of diacetyl were detected. This increase in acetylation can occur either enzymatically or chemically, a phenomenon presently demonstrated in this work.

In this experiment, we identified 93 proteins which were common between the control group and the 2,3-butanedione treated group. After this identification, we verified the peptides present in these 93 proteins, the peptides common among the groups and the incidence of acetylation in these peptides. This peptide analysis was performed to ensure that the acetylations found were due to the ingestion of 2,3-butanedione. We only validated the acetylations that were exclusively present in the treated group or that were expressed in a larger number in the treated group compared to the control group. After this analysis of the acetylated peptides, we selected 23 proteins, to which these acetylated peptides belong, and named them as 'target proteins'.

Analysis of proteins and peptides revealed that acetylation is more abundant in the group treated with 2,3-butanedione than in the control group. The proteins that exhibited this pattern of acetylation, described earlier as 'target proteins', and their respective peptides are described in [Table 2](#table-2){ref-type="table"}, which provides target protein identification and their respective peptide scores in both groups as well as descriptions of the peptide acetylation positions.
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###### Target proteins, acetylated proteins in group treated with diacetyl but non-acetylated in control group.
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  Protein I.D.    Gene I.D.   Meta score control   Meta score treated   Peptides control   Peptides treated   \*SC \[%\] control   \*SC \[%\] treated
  --------------- ----------- -------------------- -------------------- ------------------ ------------------ -------------------- --------------------
  **AL1A1_RAT**   AL1A1       269.1                253.5                11                 9                  37.1                 31.7
  **ANXA2_RAT**   ANXA2       539.6                284.6                13                 13                 44.5                 43.7
  **ANXA5_RAT**   ANXA5       411                  265                  10                 10                 37.3                 43.6
  **ASSY_RAT**    ASS1        71                   1,030.1              3                  21                 20.6                 64.3
  **BHMT1_RAT**   BHMT1       172.3                834.8                7                  24                 30                   63.1
  **CALR_RAT**    CARL        277.1                607.2                8                  13                 31.7                 49.5
  **CES1D_RAT**   CES1D       598.6                571.1                15                 16                 38.8                 50.8
  **DYH1_RAT**    DNAHC1      1,391.9              1,603.7              77                 89                 23.5                 27.7
  **EF2K_RAT**    EEF2K       354                  304.5                18                 17                 38.5                 34.1
  **ENPL_RAT**    HSP90B1     742.6                492.2                25                 16                 29.6                 23.5
  **EPHA6_RAT**   EPHA6       486.4                361.4                27                 20                 32.4                 24.5
  **FABPL_RAT**   FABPL       120.5                779.4                3                  16                 36.2                 81.9
  **G3P_RAT**     GAPDH       486.7                763                  14                 18                 53.8                 62.2
  **OGA_RAT**     MEGEA5      308.5                353.6                16                 19                 26.7                 31.6
  **PARK7_RAT**   PARK7       173.3                187.5                4                  10                 28.6                 51.3
  **PRC2A_RAT**   PRRC2A      776.2                670.4                43                 36                 25.3                 23.6
  **SI1L1_RAT**   SI1L1       575.9                672.1                32                 37                 27.9                 30.7
  **STIP1_RAT**   STIP1       189.5                258.9                10                 14                 22.1                 30
  **SYPM_RAT**    PARS2       171.2                183.4                9                  10                 32.6                 46.3
  **TBB4B_RAT**   TUBB4B      801.7                463.1                20                 15                 52.1                 48.8
  **TPP1_RAT**    TPP1        99.3                 109.3                5                  6                  9.9                  11.7
  **UBR4_RAT**    UBR4        1,600.3              1,813.1              90                 103                24.2                 30.2
  **UD2B2_RAT**   UGT2B       390.2                705.3                21                 25                 44.7                 59.1

Some peptides showed post-translational modifications, and these peptides are listed in [Table 3](#table-3){ref-type="table"}. As expected, L-lysine appears to be the predominant acetylated amino acid in the peptide sequence, although arginine and histidine residues were found to be acetylated as well.
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###### Peptides from acetylated proteins in group treated with diacetyl but non-acetylated in control group.
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  Protein I.D.   Gene I.D.   Peptide sequence                                   Peptide meta score control   Peptide meta score treated   Acetylation treated group
  -------------- ----------- -------------------------------------------------- ---------------------------- ---------------------------- ---------------------------
  AL1A1_RAT      ALDH1A1     -.MSSPAQPAVPAPLANLKIQHTK.I                         15.4                         16.1                         7; 20; 22
  ANXA2_RAT      ANXA2       K.ELPSAMKSALSGHLETVMLGLLK.T                        15                           21.7                         3; 23
  ANXA2_RAT      ANXA2       K.ELPSAMKSALSGHLETVMLGLLK.T                        15                           16.6                         3; 23
  ANXA2_RAT      ANXA2       K.GVDEVTIVNILTNR.S                                 71.9                         18.2                         14
  ANXA2_RAT      ANXA2       K.SALSGHLETVMLGLLK.T                               94                           18.6                         6
  ANXA5_RAT      ANXA5       K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S                 16.4                         16.7                         15
  ANXA5_RAT      ANXA5       K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S                 16.4                         17.6                         5; 30
  ASSY_RAT       ASS1        R.GIYETPAGTILYHAHLDIEAFTMDR.E                      39.8                         16.1                         13; 5
  BHMT1_RAT      BHMT        R.IASGRPYNPSMSKPDAWGVTK.G                          16.3                         17.5                         5
  BHMT1_RAT      BHMT        R.IASGRPYNPSMSKPDAWGVTK.G                          15.4                         15.4                         21; 30
  CALR_RAT       CALR        K.HEQNIDCGGGYVK.L                                  33                           85.7                         13
  CES1D_RAT      CES1D       K.GKVLGK.Y                                         24.4                         15.1                         2
  CES1D_RAT      CES1D       R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T                    18.5                         22.7                         2; 25
  CES1D_RAT      CES1D       R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T                    18.5                         15.7                         2; 7; 25
  DYH1_RAT       DNAH1       R.SSLTRLASHMAEYECFQVELSK.N                         19                           16.7                         5
  EF2K_RAT       EEF2K       R.SGDLYTQAAEAAMEAMK.G                              30.7                         21.1                         7
  ENPL_RAT       HSP90B1     R.MMKLIINSLYK.N                                    18.8                         16.1                         1; 3
  EPHA6_RAT      EPHA6       R.EASIMGQFDHPNIIRLEGVVTK.R                         18.3                         16.8                         0; 5
  EPHA6_RAT      EPHA6       K.SVTEFNGDTITNTMTLGDIVYK.R                         28.2                         50.8                         22
  FABPL_RAT      FABPL       K.SVTEFNGDTITNTMTLGDIVYK.R                         16                           36.2                         22
  FABPL_RAT      FABPL       K.YQVQSQENFEPFMK.A                                 28.2                         33.9                         4
  G3P_RAT        GAPDH       K.RVIISAPSADAPMFVMGVNHEK.Y                         18.6                         23.1                         1; 20; 22
  G3P_RAT        GAPDH       K.RVIISAPSADAPMFVMGVNHEK.Y                         18.6                         15.8                         20; 22
  G3P_RAT        GAPDH       K.RVIISAPSADAPMFVMGVNHEK.Y                         18.6                         15.8                         20; 22
  G3P_RAT        GAPDH       K.RVIISAPSADAPMFVMGVNHEK.Y                         18.6                         23.1                         1; 20; 22
  OGA_RAT        MGEA5       K.LDQVSQFGCRSFALLFDDIDHNMCAADK.E                   20                           15.4                         21; 28
  PARK7_RAT      PARK7       K.GAEEMETVIPVDIMR                                  28.2                         16.1                         5; 6
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         30.3                         9
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         18.9                         9
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         16.6                         21
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         26.6                         21; 32
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         19.4                         32
  PRC2A_RAT      PRRC2A      K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L               17.9                         15.1                         9
  PRC2A_RAT      PRRC2A      K.AVGTPGGNSGGAGPGISTMSRGDLSQR.A                    18.4                         22                           21; 27
  PRC2A_RAT      PRRC2A      R.ERSDSGGSSSEPFER.H                                17.1                         15.4                         15
  SI1L1_RAT      SIPA1L1     K.EKSKPYPGAELSSMGAIVWAVR.A                         15.6                         19.4                         2
  SI1L1_RAT      SIPA1L1     K.SLPLRRPSYTLGMK.S                                 19.5                         16.8                         5
  STIP1_RAT      STIP1       R.RAMADPEVQQIMSDPAMR.L                             20.7                         18.9                         1; 8
  STIP1_RAT      STIP1       R.RAMADPEVQQIMSDPAMR.L                             20.7                         20.4                         8
  SYPM_RAT       PARS2       K.GIEVGHTFYLGTKYSSIFNAHFTNA HGESLLAEMGCYGLGVTR.I   17.8                         15                           21; 26
  TBB4B_RAT      TUBB4B      R.INVYYNEATGGKYVPR.A                               21.9                         15.4                         6; 12
  TPP1_RAT       TPP1        R.EREPELAQLLVDQIYENAMIAAGLVDDPR.A                  15.2                         19.3                         29
  TPP1_RAT       TPP1        R.INTLQAIWMMDPK.D                                  15.9                         15.1                         3
  UBR4_RAT       UBR4        K.ALGTLGMTTNEKGQVVTK.T                             15.7                         21.7                         2
  UBR4_RAT       UBR4        K.EKAAPPPPPPPPPLESSPR.V                            18.3                         18.1                         2; 9
  UBR4_RAT       UBR4        K.EKEGESSGSQEDQLCTALVNQLNR.F                       17.1                         16.7                         2; 24
  UBR4_RAT       UBR4        K.FLSRPALPFILRLLR.G                                15.1                         30                           5; 12
  UBR4_RAT       UBR4        R.DNPEATQQMNDLIIGKVSTALK.G                         28.8                         17.2                         6; 22
  UBR4_RAT       UBR4        R.DNPEATQQMNDLIIGKVSTALK.G                         17.3                         21                           22
  UBR4_RAT       UBR4        R.MAGVMAQCGGLQCMLNRLAGVK.D                         19.3                         23.9                         7
  UBR4_RAT       UBR4        R.TGSTSSKEEDYESDAATIVQK.C                          19.4                         17.3                         7; 21
  UD2B2_RAT      UGT2B       K.EWDTFYSEILGRPTTVDETMSKVEIWLIR.S                  15.2                         16.8                         12; 22

The acetylation ratio from target proteins ratio was calculated in order to more effectively visualize the increase in acetylation. The increase in acetylation can be clearly seen in [Table 4](#table-4){ref-type="table"}, which shows the increase in the acetylation ratio in the peptides identified in both groups. The student's *t*-test was applied, and the difference was significant with *p* \< 0.0001, demonstrating that there was a significant increase of the acetylation in these peptides.
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###### Ratio of acetylation in both groups: control and treated with 2,3-butanedione.
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  Protein I.D.   Gene I.D.                                                       Peptide sequence                                                Acetylation ratio control group   Acetylation ratio treated group
  -------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------- ---------------------------------
  AL1A1_RAT      ALDH1A1                                                         -.MSSPAQPAVPAPLANLKIQHTK.I                                      1                                 3
  ANXA2_RAT      ANXA2                                                           K.ELPSAMKSALSGHLETVMLGLLK.T                                     0.5                               0.666666667
  ANXA2_RAT      ANXA2                                                           K.GVDEVTIVNILTNR.S                                              0                                 1
  ANXA2_RAT      ANXA2                                                           K.SALSGHLETVMLGLLK.T                                            0                                 1
  ANXA5_RAT      ANXA5                                                           K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S                              0                                 1
  ASSY_RAT       ASS1                                                            R.GIYETPAGTILYHAHLDIEAFTMDR.E                                   0                                 2
  BHMT1_RAT      BHMT                                                            R.IASGRPYNPSMSKPDAWGVTK.G                                       0                                 2
  CALR_RAT       CALR                                                            K.HEQNIDCGGGYVK.L                                               0                                 1
  CES1D_RAT      CES1D                                                           K.GKVLGK.Y                                                      0                                 1
  CES1D_RAT      CES1D                                                           R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T                                 2                                 1.5
  DYH1_RAT       DNAH1                                                           R.SSLTRLASHMAEYECFQVELSK.N                                      0                                 1
  EF2K_RAT       EEF2K                                                           R.SGDLYTQAAEAAMEAMK.G                                           0                                 1
  ENPL_RAT       HSP90B1                                                         R.MMKLIINSLYK.N                                                 0                                 2
  EPHA6_RAT      EPHA6                                                           R.EASIMGQFDHPNIIRLEGVVTK.R                                      0                                 2
  FABPL_RAT      FABPL                                                           K.SVTEFNGDTITNTMTLGDIVYK.R                                      0                                 1
  FABPL_RAT      FABPL                                                           K.YQVQSQENFEPFMK.A                                              0                                 1
  G3P_RAT        GAPDH                                                           K.RVIISAPSADAPMFVMGVNHEK.Y                                      1                                 1.5
  OGA_RAT        MGEA5                                                           K.LDQVSQFGCRSFALLFDDIDHNMCAADK.E                                0                                 2
  PARK7_RAT      PARK7                                                           K.GAEEMETVIPVDIMR                                               1                                 0.5
  PRC2A_RAT      PRRC2A                                                          K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L                            1                                 0.5
  PRC2A_RAT      PRRC2A                                                          K.AVGTPGGNSGGAGPGISTMSRGDLSQR.A                                 0                                 2
  PRC2A_RAT      PRRC2A                                                          R.ERSDSGGSSSEPFER.H                                             0                                 1
  SI1L1_RAT      SIPA1L1                                                         K.EKSKPYPGAELSSMGAIVWAVR.A                                      0                                 1
  SI1L1_RAT      SIPA1L1                                                         K.SLPLRRPSYTLGMK.S                                              0                                 1
  STIP1_RAT      STIP1                                                           R.RAMADPEVQQIMSDPAMR.L                                          0                                 1
  SYPM_RAT       PARS2                                                           K.GIEVGHTFYLGTKYSSIFNAHFTNAH GESLLAEMGCYGLGVTR.I                1                                 2
  TBB4B_RAT      TUBB4B                                                          R.INVYYNEATGGKYVPR.A                                            0                                 2
  TPP1_RAT       TPP1                                                            R.EREPELAQLLVDQIYENAMIAAGLVDDPR.A                               0                                 1
  TPP1_RAT       TPP1                                                            R.INTLQAIWMMDPK.D                                               0                                 1
  UBR4_RAT       UBR4                                                            K.ALGTLGMTTNEKGQVVTK.T                                          0                                 1
  UBR4_RAT       UBR4                                                            K.EKAAPPPPPPPPPLESSPR.V                                         0                                 2
  UBR4_RAT       UBR4                                                            K.EKEGESSGSQEDQLCTALVNQLNR.F                                    1                                 1
  UBR4_RAT       UBR4                                                            K.FLSRPALPFILRLLR.G                                             0                                 2
  UBR4_RAT       UBR4                                                            R.DNPEATQQMNDLIIGKVSTALK.G                                      2                                 3
  UBR4_RAT       UBR4                                                            R.MAGVMAQCGGLQCMLNRLAGVK.D                                      0                                 1
  UBR4_RAT       UBR4                                                            R.TGSTSSKEEDYESDAATIVQK.C                                       0                                 2
  UD2B2_RAT      UGT2B                                                           K.EWDTFYSEILGRPTTVDETMSKVEIWLIR.S                               0                                 2
  **Mean**       **0.283783784 ± 0.092 (27)[^a^](#table-4fn1){ref-type="fn"}**   **1.423423423 ± 0.104 (27)[^a^](#table-4fn1){ref-type="fn"}**                                     

**Notes.**

Mean ± Std. Error(N).

Analysis of the distribution of acetylated proteins within the subcellular localization revealed that they were predominantly located in the cellular membrane and cytoplasm (53%). Nineteen percent are known to be present in the nucleus and 12% in the cytoskeleton, while 14% are in different organelles, including mitochondria and endoplasmatic reticulum.

Protein interaction analysis
----------------------------

[Figure 2](#fig-2){ref-type="fig"} consists of the acetylated protein network from treated group. This network represents this protein interaction. Nodes represent the proteins in the network, and each color represents a different situation in relation to protein acetylation, while the edges represent the interactions between the proteins.

![Network of acetylated proteins in group treated with Diacetyl.\
The green nodes are the proteins acetylated in group treated with Diacetyl but lack acetylation on treated groups. The red nodes are the proteins presents only in group treated with Diacetyl; the blue nodes are the proteins presents only in control group and the purple nodes are proteins present in both groups.](peerj-06-4688-g002){#fig-2}

Orthology analyses
------------------

In order to reveal the involved cellular and metabolic processes as well as the subcellular location of the differentially expressed proteins in acetylation level with 2,3-butanedione treatment, the GO-based analysis was conducted.

Analysis of the Molecular Function ([Fig. 3A](#fig-3){ref-type="fig"}) revealed catalytic activity (57%), followed by specific binding function (19%). The analyses of biological functions ([Fig. 3B](#fig-3){ref-type="fig"}) indicated some processes in which acetylated proteins are involved, including cellular processes (28.6%) and responses to stimulus (14.3%). The top three protein classes ([Fig. 3C](#fig-3){ref-type="fig"}) display hydrolase (19%), chaperone (14.3 %) and oxidoreductase (14.3 %) activities. The cellular component analyses ([Fig. 3D](#fig-3){ref-type="fig"}) demonstrated that acetylated proteins belong to macromolecular complexes (9.5%), cell organelles (9.5%), extracellular region (4.8%) and other cell parts (19%).

![Orthology analyses from more acetylated proteins in group treated with Diacetil than in control group.\
(A) Molecular function; (B) biological process; (C) protein class; (D) cellular component.](peerj-06-4688-g003){#fig-3}

Motif analysis of proteins containing arginine-, lysine- and histidine-acetylated peptides
------------------------------------------------------------------------------------------

In order to characterize the possible specific sequence motifs surrounding acetylated arginine, lysine and histidine residues in peptides of lung samples, a logo sequence to compute the likelihood of amino acids at the positions surrounding the acetylation site was generated. Ten significantly enriched motifs were obtained from all the identified acetylated sites including \*K, \*R, \*H (\*K represents the acetylated lysine, \*R represents the acetylated arginine and \*H represents the acetylated histidine). As shown in [Fig. 4](#fig-4){ref-type="fig"}, logos with the highest scores were used and all motif analyses are available in SM 2--7. [Figures 4A](#fig-4){ref-type="fig"} and [4D](#fig-4){ref-type="fig"} show the motif surrounding acetylated arginine in samples from the control and treated groups, respectively, and [Figs. 4B](#fig-4){ref-type="fig"} and [4E](#fig-4){ref-type="fig"} show the motif surrounding acetylated lysine. A number of reports have already demonstrated the occurrence of acetylation in arginine residue ([@ref-19]). [Figures 4C](#fig-4){ref-type="fig"} and [4F](#fig-4){ref-type="fig"} portray the motif surrounding acetylated histidine from control and groups treated with diacetyl, respectively.

![Motif analysis surrounding arginine, lysine and histidine acetylated peptides.\
(A) Motif analysis of control group, surrounding acetylated arginine. (B) Motif analysis of control group, surrounding acetylated lysine. (C) Motif analysis of control group, surrounding acetylated histidine. (D) Motif analysis of group treated with diacetyl, surrounding arginine. (E) Motif analysis of group treated with diacetyl, surrounding lysine. (F) Motif analysis of group treated with diacetyl, surrounding histidine.](peerj-06-4688-g004){#fig-4}

Western blotting
----------------

Western blotting experiments indicated that the acetylation level was significantly higher in the treated group as compared to the control group ([Fig. 5](#fig-5){ref-type="fig"}). [Figure 5A](#fig-5){ref-type="fig"} shows an increase in acetylation in bands that correspond between 35--70 KDa in lanes 5,7 and 8 that were filled with samples from the group treated with 2,3-butanedione. The wells filled with samples from the control group (lanes: 2--4) did not display the acetylation band.

![Western blotting for acetylated proteins from lung samples.\
(A) Western blotting 4 image: Lane 1: molecular weight; lanes 2--4: samples of the control group; lanes 5, 7, and 8: samples 5 of the diacetyl-treated group; and lanes 6, 9, and 10: sample buffer. (B) Western blotting quantification.](peerj-06-4688-g005){#fig-5}

Statistical analysis by the Student *t*-test revealed that mean values of protein intensities and variances are significantly different, with *p* = 0.0091 for means and *p* = 0.0015 for variance. This Western blotting experiment data confirms the result of LC-MS/MS analysis, which revealed increases in protein acetylation from the group treated with 2,3-butanedione in comparison with the control group.

Discussion
==========

Protein extraction optimization
-------------------------------

The amount of proteins obtained from precipitated and resolubilizated proteins using three buffers. Buffers 1 and 2 were slightly more efficient than Buffer 3, which led us to choose Buffer 2 in all experiments.

MS/MS analyses of rat lung proteins
-----------------------------------

The results from provide evidence of an increase in protein acetylation in the group treated with diacetyl. Acetylation reportedly alters protein function, size, enzymatic activity, stability, protein-protein interactions and other protein properties. Some proteins regulate acetyltransferases and histone deacetylases and may induce acetylation of other proteins ([@ref-8]). When acetyltransferases are deregulated, and lysine acetylation is increased, modifications may occur in genes and the regulatory machinery ([@ref-8]). These data show that diacetyl- triggered protein acetylation takes place in different cell compartments and that it may be implicated in many cell functions.

Protein interaction analysis
----------------------------

The protein interaction analysis showed that some acetylated proteins are interconnected and/or connected with other proteins. To exemplify this interaction, we can cite the protein ASS1, found to be acetylated in the treated group, which interacts with both ALS and OTC. Present in our control group is the ALS enzyme, whose activity is regulated by acetylation, according to the UniProt database (<http://www.uniprot.org>). ASS1 interacts with OTC, which is present only in the diacetyl-treated group. OTC, one of the enzymes of the urea cycle, acts by detoxifying the excess of ammonium produced from amino acid catabolism and is negatively regulated by lysine acetylation ([@ref-39]).

Some acetylated proteins present in the network are involved in the cell redox balance ([@ref-8]), in protein biosynthesis and have ATP and nucleotide binding activity, maturation, structural maintenance and regulation of specific proteins ([@ref-11]), along with cellular processes such as the basal metabolism, immunogenicity, cell cycle progression, DNA repair and apoptosis ([@ref-24]). Some proteins also induce anti-tumor immunity by inhibiting angiogenesis and have antioxidant activity in neurons and the heart, protecting against cell death ([@ref-14]; [@ref-34]). Additionally, the proteins play a cytoprotective role being a redox-responsive protein ([@ref-10]).

The increase in chemical acetylation of lung proteins of diacetyl-treated rats described here may be connected with the fact that diacetyl has been shown *in vitro* to generate acetyl radicals upon reaction with peroxynitrite, and more slowly with hydrogen peroxide ([@ref-37]). The diacetyl/peroxynitrite system was then reported to promote acetylation of isolated amino acids, peptides and albumin. These data led us to postulate that post-translational chemical acetylation of proteins may contribute to enzymatic acetylation at sites where both diacetyl and peroxynitrite at inflammation are formed.

Orthology analyses
------------------

The Gene Ontology (GO) function analysis of the target proteins revealed the distribution and function of these proteins. Protein acetylation regulates enzyme activities that mediate, for instance, the degradation of proteasomes and lysosomes by neutralizing the lysine residues in the active sites, thereby causing conformational changes. In addition to regulating the catalytic activity of metabolic enzymes, acetylation controls substrate accessibility, blocks substrate binding to the enzyme and modulates enzyme subcellular localization ([@ref-38]).

The most crucial pathways are those related to the oxidative stress response (P00046), which causes cellular damage. In a normal functioning cell, several transcription factors respond to oxidative stress by modulating the expression of genes whose products relieve the altered redox status.

Motif analysis of proteins containing arginine-, lysine- and histidine-acetylated peptides
------------------------------------------------------------------------------------------

The possible motifs surround acetylated arginine, lysine and histidine. Despite lysine being the more common site of protein acetylation, some studies have demonstrated that arginine can be acetylated as well, triggering biological responses ([@ref-29]; [@ref-35]). Acetylation in both lysine and histidine residue was previously demonstrated *in vitro* ([@ref-1]; [@ref-18]; [@ref-17]; [@ref-37]), which reinforces our results about acetylation in these residues.

Western blotting
----------------

Western blotting was used to confirm the increase of acetylation previously found by NanoLc-ms/ms experiments. We used a specific acetylation antibody to detect bands with a substantial increase in intensity in samples from the group treated with diacetyl that reveals the protein acetylation increase. These results confirm the protein acetylation identified by NanoLc-ms/ms analyses.

Conclusions
===========

Altogether, our data strongly suggest that diacetyl gavage administered to rats may constitute a source of acetyl radical that can attack and acetylate lung proteins. It is tempting to hypothesize that this is a contribution mechanism for the reported toxicity of diacetyl in workers dealing with 'buttered' food who subsequently acquire bronquiolitis obliterans.

Herein, we first optimized extraction conditions for the lung proteins of Wistar rats, for both rats in the control group and those treated with diacetyl. Mass spectrometry results, confirmed by Western blotting analyses, revealed increased acetylation in the lung tissues of groups treated with 2,3-butanedione.

The proteins acetylated to different extents in the diacetyl-treated group were then related to reported interactions with other key proteins and enzymes of cell homeostasis. Diacetyl treatment, apparently, modifies the lung protein profile. Twenty-three diverse classes of proteins were found to undergo preferential acetylation. They are present in different regions of the cell and are involved in different molecular and biological processes. Our data indicate that the observed increased radical acetylation by diacetyl occurs randomly.

In a comprehensive view, we found more peptides acetylated in the group treated with diacetyl than in the control group. The expected acetylation of lysine residues also occurred in arginine and histidine, suggesting that unlike acetylase-driven acetylation of proteins, radical acetylation occurs randomly, modifying residues of both the N-terminal, the C-terminal and the side chain of basic amino acid residues. The Western blotting analysis clearly demonstrated increased protein acetylation due to the daily intake of diacetyl.

Our study is consistent with early *in vitro* studies that showed increases in protein acetylation in the presence of 2,3-butanedione. The data reported here reinforce our hypothesis that diacetyl exposure is capable of increasing protein acetylation *in vivo*, thus raising a potential for diacetyl, a highly electrophilic α-dicarbonyl industrial xenobiotic, to play a role in inflammatory bronquiolitis obliterans ([@ref-4]; [@ref-7]; [@ref-9]).
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###### NanoHPLC gradient elution

NanoHPLC gradient elution, gradient mobile phase consisting of (A) formic acid/ACN/ H2O (1:20:980) and (B) formic acid/ACN/ H2O (1:950:50).
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Click here for additional data file.
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###### Central residue H acetylated (control group)

Motif analysis of Lung from control group. Central residue H acetylated.
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Click here for additional data file.
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###### Central residue H acetylated in group treated with 540 mg/Kg/day of Diacetyl

Motif analysis of Lung from group treated with 540 mg/Kg/day of Diacetyl. Central residue H acetylated.

###### 

Click here for additional data file.

10.7717/peerj.4688/supp-4

###### Central residue K acetylated in group treated with 540 mg/Kg/day of Diacetyl

Motif analysis of Lung from group treated with 540 mg/Kg/day of Diacetyl. Central residue K acetylated.

###### 

Click here for additional data file.
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###### Central residue K acetylated in control group

Motif analysis of Lung from control group. Central residue K acetylated.

###### 

Click here for additional data file.
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###### Central residue R acetylated in group treated with 540 mg/Kg/day of Diacetyl

Motif analysis of Lung from group treated with 540 mg/Kg/day of Diacetyl. Central residue R acetylated.

###### 

Click here for additional data file.
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###### Central residue R acetylated in control group

Motif analysis of Lung from control group. Central residue R acetylated.

###### 

Click here for additional data file.
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###### Western blotting

Western Blotting individual data.

###### 

Click here for additional data file.

ANXA2

:   Annexin-A2

ANXA5

:   Annexin-A5

ASS1

:   Argininosuccinate synthase

BHMT1

:   Betaine-homocysteine S-methyltransferase-1

CALR

:   Calreticulin

CHAPS

:   3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate

ES1D

:   Carboxylesterase-1D

DTT

:   Dithiothreitol

DNAH1

:   Dynein heavy chain-1

EF2K

:   Eukaryotic elongation factor-2 kinase

HSP90B1

:   Endoplasmin

EPHA6

:   Ephrin type-A receptor

FABPL

:   Fatty acid-binding protein

GAPDH

:   Glyceraldehyde-3-phosphate dehydrogenase

MGEA5

:   O-GlcNAcase

PARK7

:   Deglycase DJ-1

PARS2

:   Protein Probable proline-tRNA ligase PBS\] Phosphate-buffered saline

PMSF

:   Phenylmethylsulfonyl fluoride

SIPA1L1

:   Signal-induced proliferation-associated 1-like protein-1

STIP1

:   Stress-induced-phosphoprotein-1

TUBB4B

:   Tubulin beta-4B chain

TFA

:   Trifluoroacetic acid

UBR4

:   Ubiquitin-protein ligase

UGT2B

:   UDP-glucuronosyl- transferase-2B2.
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